PharmaEd Resources · La Jolla, CA · December 2–3, 2026
Aseptic Processing Summit 2026
Juergen M. Metzger is scheduled to present at PharmaEd Resources’ Aseptic Processing Summit 2026 in La Jolla, California.
FDA Warning Letters: Root Cause Analysis and Technology Enablers in Aseptic Manufacturing
The session examines contamination risks associated with human and glove interventions in aseptic manufacturing, current EU GMP Annex 1 and FDA expectations, Human Performance principles, and technology approaches intended to reduce manual intervention.
Why this topic matters
Aseptic manufacturing performance depends on more than the presence of a barrier system. Human and glove interventions, equipment and transfer concepts, operating practices and contamination-control measures must work together as an integrated system. The session uses observations from FDA warning letters and current regulatory expectations to examine where recurring weaknesses can arise and how technology can help reduce intervention-related risk.
Gloveless processing, robotics, sensors and vision systems can reduce dependence on manual intervention, but technology alone does not establish a robust contamination control strategy. Successful implementation requires appropriate process design, equipment integration, operating discipline and a clear understanding of the residual risks that remain.
Related PTC expertise: Aseptic Fill-Finish Consulting, Barrier Systems & Isolators and Aseptic Processes.
Session focus
- Human interventions as a persistent source of contamination risk
- Glove interventions and barrier-system operating concepts
- EU GMP Annex 1 and FDA expectations
- Human Performance principles in aseptic operations
- Gloveless aseptic processing and robotics
- Sensors and vision systems as technology enablers
Speaker
The official PharmaEd conference program lists Juergen M. Metzger as CEO of Pharma-Technology-Consulting for this presentation.
Metzger’s work focuses on aseptic fill-finish, isolators and RABS, barrier and transfer technology, Annex 1 implementation and the technical and project-governance interfaces that influence pharmaceutical manufacturing performance.